Corrected Calcium
Adjusts serum calcium for albumin level to obtain true calcium status.
Score interpretation
Corrected Ca²⁺ < 2.2 mmol/L: Hypocalcaemia.
→ Mild (2.0–2.2): Oral calcium supplements + vitamin D. Severe (<1.9) / symptomatic: IV calcium gluconate 10% 10ml over 10 min. Check PTH, vitamin D, phosphate, Mg²⁺.
Corrected Ca²⁺ 2.2–2.6 mmol/L: Normal range.
→ No acute intervention required.
Corrected Ca²⁺ 2.6–3.0 mmol/L: Mild hypercalcaemia.
→ Investigate: PTH (primary hyperparathyroidism), malignancy, sarcoidosis, medications. IV fluids if dehydrated. Check PTH, PTHrP, 25-OH vitamin D.
Corrected Ca²⁺ 3.0–3.5 mmol/L: Moderate hypercalcaemia. Symptomatic.
→ IV 0.9% saline 2–4 L/day. IV bisphosphonate (zoledronic acid 4 mg or pamidronate 60–90 mg). Consider calcitonin for rapid effect.
Corrected Ca²⁺ > 3.5 mmol/L: Hypercalcaemic crisis. Life-threatening.
→ EMERGENCY. Aggressive IV saline. IV bisphosphonate URGENTLY. Haemodialysis if refractory. HDU. Treat underlying cause.
Interpretation bands for the Corrected Ca²⁺. Apply clinical judgement and local guidance.
References
- Payne RB et al. Interpretation of serum total calcium. BMJ. 1973.
Related
Curated clinical cross-links plus same-class fallbacks.
- Levosimendan (ICU — Calcium Sensitiser) · Inodilator — Calcium Sensitiser
- Calcium Gluconate · Electrolyte — Calcium Supplement
- Levosimendan · Calcium Sensitiser / Inodilator
- Verapamil · Non-Dihydropyridine Calcium Channel Blocker
- Diltiazem · Non-Dihydropyridine Calcium Channel Blocker
- Felodipine · Dihydropyridine calcium-channel blocker
- Sepsis Screening and Sepsis Six · UK Sepsis Trust; NICE NG51; Surviving Sepsis Campaign 2021
- Unintentional Weight Loss Workup · NICE NG12; BSG
- Chronic Fatigue Workup · NICE NG206; BMJ Best Practice
- Lymphadenopathy Workup · NICE NG12; BMJ Best Practice
- Pre-op Medical Clearance · NICE NG45; ESC 2022
- Secondary Hypertension Workup · NICE NG136; ESH 2023
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.